PT1713458E - Método para aumentar a biodisponibilidade do ospemifeno - Google Patents

Método para aumentar a biodisponibilidade do ospemifeno Download PDF

Info

Publication number
PT1713458E
PT1713458E PT05701734T PT05701734T PT1713458E PT 1713458 E PT1713458 E PT 1713458E PT 05701734 T PT05701734 T PT 05701734T PT 05701734 T PT05701734 T PT 05701734T PT 1713458 E PT1713458 E PT 1713458E
Authority
PT
Portugal
Prior art keywords
ospemifene
food
compound
use according
ingestion
Prior art date
Application number
PT05701734T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1713458(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of PT1713458E publication Critical patent/PT1713458E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
PT05701734T 2004-02-13 2005-01-14 Método para aumentar a biodisponibilidade do ospemifeno PT1713458E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/777,211 US8236861B2 (en) 2004-02-13 2004-02-13 Method for enhancing the bioavailablity of ospemifene

Publications (1)

Publication Number Publication Date
PT1713458E true PT1713458E (pt) 2008-05-07

Family

ID=34837941

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05701734T PT1713458E (pt) 2004-02-13 2005-01-14 Método para aumentar a biodisponibilidade do ospemifeno

Country Status (23)

Country Link
US (5) US8236861B2 (forum.php)
EP (1) EP1713458B1 (forum.php)
JP (2) JP5577011B2 (forum.php)
CN (1) CN1925847A (forum.php)
AT (1) ATE387910T1 (forum.php)
AU (1) AU2005211958B2 (forum.php)
BE (1) BE2015C033I2 (forum.php)
BR (1) BRPI0507661A (forum.php)
CA (1) CA2556089C (forum.php)
CY (2) CY1111014T1 (forum.php)
DE (1) DE602005005165T2 (forum.php)
DK (1) DK1713458T5 (forum.php)
ES (1) ES2302177T3 (forum.php)
FR (1) FR15C0041I2 (forum.php)
HU (1) HUS1500030I1 (forum.php)
LT (1) LTC1713458I2 (forum.php)
LU (1) LU92736I2 (forum.php)
MX (1) MXPA06009274A (forum.php)
NO (2) NO337656B1 (forum.php)
PL (1) PL1713458T3 (forum.php)
PT (1) PT1713458E (forum.php)
RU (1) RU2385716C2 (forum.php)
WO (1) WO2005077350A1 (forum.php)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
EP1742618B1 (en) 2004-05-04 2012-08-22 Hormos Medical Ltd. Liquid oral formulations of ospemifene
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
CN101304738A (zh) * 2005-11-09 2008-11-12 霍尔莫斯医疗有限公司 非培米芬的制剂
EP1954670A4 (en) * 2005-11-28 2011-04-27 Gtx Inc NUCLEAR RECEPTOR BINDING AGENTS
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
PL2121553T3 (pl) * 2007-02-14 2012-11-30 Hormos Medical Ltd Sposób wytwarzania cennych terapeutycznie pochodnych trifenylobutenu
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
JP6174156B2 (ja) 2012-10-19 2017-08-02 フェルミオン オサケ ユキチュア オスペミフェンの製造方法
CN103739456A (zh) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 2-（对-（（z-4-氯-1,2-二苯基-1-丁烯基）苯氧基）乙醇的新型衍生物及其应用
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
EP4279133A3 (en) 2018-05-11 2024-02-21 Xenon Pharmaceuticals Inc. Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener
CN119100981A (zh) 2019-10-10 2024-12-10 泽农医药公司 一种选择性钾通道调节剂的固态结晶形式
MX2022005490A (es) 2019-11-08 2022-08-10 Xenon Pharmaceuticals Inc Metodos para el tratamiento de trastornos depresivos.
KR20240004241A (ko) 2021-02-09 2024-01-11 제논 파마슈티칼스 인크. 무쾌감증의 치료에 사용하기 위한 전압-게이트 칼륨 채널 오프너

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
US6262098B1 (en) * 1998-08-07 2001-07-17 Chiron Corporation Estrogen receptor modulators
US6219674B1 (en) * 1999-11-24 2001-04-17 Classen Immunotherapies, Inc. System for creating and managing proprietary product data
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6653639B1 (en) * 2000-10-17 2003-11-25 Nikon Corporation Chuck for mounting reticle to a reticle stage
AU2002255593A1 (en) 2001-02-22 2002-09-12 Classen Immunotherapies, Inc. Improved algorithms and methods for products safety
FR2826811B1 (fr) 2001-06-27 2003-11-07 France Telecom Procede d'authentification cryptographique
DE60309465T2 (de) 2002-06-06 2007-08-30 Hormos Medical Ltd. Verfahren zur Hemmung oder Vorbeugung von urogenitaler Atrophie und deren Symptome bei Frauen
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US20050187302A1 (en) * 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
KR100665758B1 (ko) * 2005-09-15 2007-01-09 제일모직주식회사 반사방지성을 갖는 하드마스크 조성물

Also Published As

Publication number Publication date
CN1925847A (zh) 2007-03-07
HUS1500030I1 (hu) 2015-08-28
US20140303259A1 (en) 2014-10-09
CA2556089A1 (en) 2005-08-25
US20160101065A1 (en) 2016-04-14
US8236861B2 (en) 2012-08-07
US20130324614A1 (en) 2013-12-05
US20120270952A1 (en) 2012-10-25
NO337656B1 (no) 2016-05-23
JP5577011B2 (ja) 2014-08-20
CY1111014T1 (el) 2015-06-11
ATE387910T1 (de) 2008-03-15
RU2006132719A (ru) 2008-03-20
US8772353B2 (en) 2014-07-08
NO20151603L (no) 2006-11-03
DK1713458T5 (da) 2008-09-29
AU2005211958B2 (en) 2010-11-25
ES2302177T3 (es) 2008-07-01
DE602005005165T2 (de) 2009-04-30
NO20063960L (no) 2006-11-03
JP2014141533A (ja) 2014-08-07
LU92736I2 (fr) 2015-08-10
PL1713458T3 (pl) 2008-08-29
RU2385716C2 (ru) 2010-04-10
DK1713458T3 (da) 2008-07-07
FR15C0041I1 (forum.php) 2015-07-17
BRPI0507661A (pt) 2007-07-17
US9241915B2 (en) 2016-01-26
EP1713458B1 (en) 2008-03-05
MXPA06009274A (es) 2007-04-16
JP2007522190A (ja) 2007-08-09
BE2015C033I2 (forum.php) 2024-08-08
CA2556089C (en) 2013-04-02
NO339190B1 (no) 2016-11-14
JP6023119B2 (ja) 2016-11-09
CY2015027I1 (el) 2016-04-13
US20050182143A1 (en) 2005-08-18
LTPA2015023I1 (lt) 2015-08-25
DE602005005165D1 (de) 2008-04-17
EP1713458A1 (en) 2006-10-25
FR15C0041I2 (fr) 2015-11-13
CY2015027I2 (el) 2016-04-13
US8470890B2 (en) 2013-06-25
AU2005211958A1 (en) 2005-08-25
LTC1713458I2 (lt) 2017-06-26
WO2005077350A1 (en) 2005-08-25
US9855224B2 (en) 2018-01-02

Similar Documents

Publication Publication Date Title
US9855224B2 (en) Method for enhancing the bioavailability of ospemifene
CA2626337C (en) Reduction of side effects from aromatase inhibitors used for treating breast cancer
JP2020510678A (ja) 対象におけるマイトファジーを改善するための方法
Bjarnason et al. Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol‐fed rabbits
AU2017206480A1 (en) Composition, containing Loganin or a derivative thereof as an active ingredient for preventing, remedying, or treating female climacteric syndrome
JPWO2007069744A1 (ja) メタボリックシンドローム予防・改善用組成物
Gao et al. Oat fiber attenuates circulating oxysterols levels and hepatic inflammation via targeting TLR4 signal pathway in LDL receptor knockout mice
KR101304536B1 (ko) 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 간질환의 치료 또는 예방용 조성물
KR20070022220A (ko) 오스페미펜의 생물학적 이용가능성 강화방법
EP1742618B1 (en) Liquid oral formulations of ospemifene
السواحلى et al. Therapeutic effect of chia seeds (Salvia Hispanic L.) on rats with obesity and osteoporosis
Lee et al. Scenario 4: Choice of hormone replacement therapy (HRT)
EP2399583B1 (en) Use of vaginally-administered insulin sensitizing agents
JP2023553438A (ja) 少なくとも１つのグリシン若しくはその誘導体及び／又は少なくとも１つのｎ－アセチルシステイン若しくはその誘導体と、少なくとも１つのチモール及び／又はカルバクロールと、を使用する組成物及び方法
JP2024511326A (ja) トルセミドおよびクロモリンを含む代謝疾患予防または治療用組成物
KR20240027623A (ko) 여성형 유방 및/또는 유방통 치료
FYTILI SCHOOL OF MEDICINE 1st DEPARTMENT OF PROPAEDEUTIC INTERNAL MEDICINE Director: Professor P. Sfikakis
JP2019524860A (ja) 非アルコール性脂肪肝疾患の治療法